These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1789 related items for PubMed ID: 16284991

  • 1. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases.
    Pal T, Permuth-Wey J, Betts JA, Krischer JP, Fiorica J, Arango H, LaPolla J, Hoffman M, Martino MA, Wakeley K, Wilbanks G, Nicosia S, Cantor A, Sutphen R.
    Cancer; 2005 Dec 15; 104(12):2807-16. PubMed ID: 16284991
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
    Satagopan JM, Boyd J, Kauff ND, Robson M, Scheuer L, Narod S, Offit K.
    Clin Cancer Res; 2002 Dec 15; 8(12):3776-81. PubMed ID: 12473589
    [Abstract] [Full Text] [Related]

  • 4. BRCA2, but not BRCA1, mutations account for familial ovarian cancer in Iceland: a population-based study.
    Rafnar T, Benediktsdottir KR, Eldon BJ, Gestsson T, Saemundsson H, Olafsson K, Salvarsdottir A, Steingrimsson E, Thorlacius S.
    Eur J Cancer; 2004 Dec 15; 40(18):2788-93. PubMed ID: 15571962
    [Abstract] [Full Text] [Related]

  • 5. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada.
    Risch HA, McLaughlin JR, Cole DE, Rosen B, Bradley L, Fan I, Tang J, Li S, Zhang S, Shaw PA, Narod SA.
    J Natl Cancer Inst; 2006 Dec 06; 98(23):1694-706. PubMed ID: 17148771
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Incidence of BRCA1 and BRCA2 mutations in 54 Chilean families with breast/ovarian cancer, genotype-phenotype correlations.
    Gallardo M, Silva A, Rubio L, Alvarez C, Torrealba C, Salinas M, Tapia T, Faundez P, Palma L, Riccio ME, Paredes H, Rodriguez M, Cruz A, Rousseau C, King MC, Camus M, Alvarez M, Carvallo P.
    Breast Cancer Res Treat; 2006 Jan 06; 95(1):81-7. PubMed ID: 16261400
    [Abstract] [Full Text] [Related]

  • 9. The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain.
    Milne RL, Osorio A, Cajal TR, Vega A, Llort G, de la Hoya M, Díez O, Alonso MC, Lazaro C, Blanco I, Sánchez-de-Abajo A, Caldés T, Blanco A, Graña B, Durán M, Velasco E, Chirivella I, Cardeñosa EE, Tejada MI, Beristain E, Miramar MD, Calvo MT, Martínez E, Guillén C, Salazar R, San Román C, Antoniou AC, Urioste M, Benítez J.
    Clin Cancer Res; 2008 May 01; 14(9):2861-9. PubMed ID: 18451254
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Histology of prophylactically removed ovaries from BRCA1 and BRCA2 mutation carriers compared with noncarriers in hereditary breast ovarian cancer syndrome kindreds.
    Casey MJ, Bewtra C, Hoehne LL, Tatpati AD, Lynch HT, Watson P.
    Gynecol Oncol; 2000 Sep 01; 78(3 Pt 1):278-87. PubMed ID: 10985881
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Hereditary ovarian cancer.
    Prat J, Ribé A, Gallardo A.
    Hum Pathol; 2005 Aug 01; 36(8):861-70. PubMed ID: 16112002
    [Abstract] [Full Text] [Related]

  • 14. Polymorphisms in BRCA1 and BRCA2 and risk of epithelial ovarian cancer.
    Wenham RM, Schildkraut JM, McLean K, Calingaert B, Bentley RC, Marks J, Berchuck A.
    Clin Cancer Res; 2003 Oct 01; 9(12):4396-403. PubMed ID: 14555511
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer.
    Chetrit A, Hirsh-Yechezkel G, Ben-David Y, Lubin F, Friedman E, Sadetzki S.
    J Clin Oncol; 2008 Jan 01; 26(1):20-5. PubMed ID: 18165636
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Sex ratio distortion in offspring of families with BRCA1 or BRCA2 mutant alleles: an ascertainment bias phenomenon?
    Balmaña J, Díez O, Campos B, Majewski M, Sanz J, Alonso C, Baiget M, Garber JE.
    Breast Cancer Res Treat; 2005 Aug 01; 92(3):273-7. PubMed ID: 16155798
    [Abstract] [Full Text] [Related]

  • 19. Demographic and genetic characteristics of patients with borderline ovarian tumors as compared to early stage invasive ovarian cancer.
    Gotlieb WH, Chetrit A, Menczer J, Hirsh-Yechezkel G, Lubin F, Friedman E, Modan B, Ben-Baruch G, National Israel Ovarian Cancer Study Group.
    Gynecol Oncol; 2005 Jun 01; 97(3):780-3. PubMed ID: 15893369
    [Abstract] [Full Text] [Related]

  • 20. The lifetime risks of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
    Satagopan JM, Offit K, Foulkes W, Robson ME, Wacholder S, Eng CM, Karp SE, Begg CB.
    Cancer Epidemiol Biomarkers Prev; 2001 May 01; 10(5):467-73. PubMed ID: 11352856
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 90.